Monoclonal antibody used for arthritis may help severe COVID-19, study suggests
Tocilizumab, a drug used to treat some forms of arthritis, might be an effective treatment for those with severe cases of COVID-19, according to the preliminary findings of a study. (Source: Health News - UPI.com)
Source: Health News - UPI.com - April 30, 2020 Category: Consumer Health News Source Type: news

Janssen Announces Submission of Two Applications to U.S. FDA Seeking Approval of SIMPONI ARIA ® (golimumab) for the Treatment of Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis
HORSHAM, PA, April 24, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of two supplemental Biologics License Applications (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of SIMPONI ARIA® (golimumab) for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) and juvenile psoriatic arthritis (jPsA), in patients two years of age and older in combination with methotrexate. If approved for these indications, SIMPONI ARIA would be the first anti-tumor necrosis factor (TNF)-alpha biologic agent administered by intravenous infusion available...
Source: Johnson and Johnson - April 24, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Hundreds of critically-ill coronavirus patients will be given an arthritis drug in RECOVERY trial
Tocilizumab, sold as Actemra, will be given to British patients, as part of the Recovery trial, whose lungs have become severely inflamed due to an immune overreaction caused by the virus. (Source: the Mail online | Health)
Source: the Mail online | Health - April 21, 2020 Category: Consumer Health News Source Type: news

Eli Lilly to begin testing of baricitinib in COVID-19 patients
Trial is testing if anti-inflammatory (AA) response in rheumatoid arthritis patients on baricitinib will benefit COVID-19 patients as there is anecdotal evidence of benefit with AA drugs like tocilizumab in patients who have severe immune response due to COVID-19. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 15, 2020 Category: Consumer Health News Source Type: news

Case Study Shows Efficacy from Tocilizumab in Patient With COVID-19, Myeloma
A case study of a patient in Wuhan, China demonstrated that tocilizumab may be an effective treatment for very ill patients with COVID-19 who also have multiple myeloma and other blood cancers. (Source: CancerNetwork)
Source: CancerNetwork - April 9, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Chugai Starts Phase III Clinical Trial of Actemra for COVID-19 Pneumonia in Japan
Dear Investor, Please find attached a press release by Chugai:https://www.roche.com/200408e-ACT-COVID-19-trial.pdf Do not hesitate to contact us for any further questions. With best regards, (Source: Roche Investor Update)
Source: Roche Investor Update - April 8, 2020 Category: Pharmaceuticals Source Type: news

First Report of MM Patient Treated for COVID-19 With Tocilizumab First Report of MM Patient Treated for COVID-19 With Tocilizumab
Investigators from China reported the first case of COVID-19 in a patient with multiple myeloma who was successfully treated with the humanized anti-IL-6 receptor antibody tocilizumab.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 8, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Second study will assess sarilumab for Covid-19
The Phase II/III trial will evaluate the IL-6 inhibitor in the treatment of Covid-19 patients in Italy, Spain, Germany, France, Japan, Canada and Russia. This is the second trial of its kind, following anecdotal reports that tocilizumab showed efficacy in treating these patients. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 3, 2020 Category: Consumer Health News Source Type: news

Case study: Treating COVID-19 in a patient with multiple myeloma
(American Society of Hematology) A case study of a patient in Wuhan, China, suggests that the immunosuppressant tocilizumab may be an effective COVID-19 treatment for very ill patients who also have multiple myeloma and other blood cancers. The report, published in Blood Advances, also suggests that blood cancer patients may have atypical COVID-19 symptoms. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 3, 2020 Category: Infectious Diseases Source Type: news

FDA Approves Phase III Clinical Trial of Tocilizumab for COVID-19 Pneumonia
The FDA has approved a phase III clinical trial to assess the safety and efficacy of intravenous tocilizumab (Actemra) plus standard of care in hospitalized adult patients with severe COVID-19 pneumonia. (Source: CancerNetwork)
Source: CancerNetwork - March 26, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Roche response to COVID-19 pandemic
Basel, 24 March 2020 - Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today provided an update on the various actions the company is taking to address the COVID-19 pandemic.Roche initiates global phase III study and collects data on Actemra ’s potential utility in severe COVID-19 pneumonia patientsOn March 19, 2020, Roche confirmed initiation of a randomised, double-blind, placebo-controlled Phase III clinical trial in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), a part of the US Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR). The stud...
Source: Roche Investor Update - March 24, 2020 Category: Pharmaceuticals Source Type: news

Roche initiates Phase III clinical trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 pneumonia
Roche (SIX: RO, ROG; OTCQX: RHHBY) is working with the Food & Drug Administration (FDA) to initiate a randomised, double-blind, placebo-controlled Phase III clinical trial in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), a part of the US Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR), to evaluate the safety and efficacy of Actemra®/RoActemra® (tocilizumab) plus standard of care in hospitalised adult patients with severe COVID-19 pneumonia compared to placebo plus standard of care. (Source: World Pharma News)
Source: World Pharma News - March 19, 2020 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Roche test Actemra in coronavirus patients as firms re-purpose drugs
Roche will test its arthritis drug Actemra in patients with coronavirus-linked pneumonia, the Swiss drugmaker said on Thursday, joining other pharmaceutical companies seeking to re-purpose existing medicines to fight the epidemic. (Source: Reuters: Health)
Source: Reuters: Health - March 19, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

Roche initiates Phase III clinical trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 pneumonia
Basel, 19 March 2020- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced   we are working with the Food& Drug Administration (FDA) to initiate a randomised, double-blind, placebo-controlled Phase III clinical trial in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), a part of the US Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR), to evaluate the safety and efficacy of Actemra ®/RoActemra® (tocilizumab) plus standard of care in hospitalised adult patients with severe COVID-19 pneumonia compared to placebo plus standard of care. Th...
Source: Roche Media News - March 19, 2020 Category: Pharmaceuticals Source Type: news